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Abstract:
Background:Viral warts (verrucae) are extremely common. Although many will spontaneously disappear
without treatment, treatment may be sought for a variety of reasons such as discomfort. There are a number of
different treatments for cutaneous warts, with salicylic acid, immunotherapy and cryotherapy using liquid
nitrogen being two of the most common forms of treatment. Objective:To determine the efficacy of intralesional
MMR vaccine versus cryotherapy in the treatment of viral warts. Material and Methods: Patients were
randomly allocated in to two groups by lottery method. Group A, having 32 patients, was injected with
intralesional MMR vaccine (0.3ml) into the largest wart using an insulin syringe. The injection was given on
alternate weeks for maximum of 5 sessions. Group B, also having 32 patients, was given cryotherapy by
applying liquid nitrogen with a cotton tip applicator for 10 to 30 seconds until the ice ball formation spreads to
involve 1mm margin of surrounding normal skin, at weekly interval for maximum of 8 sessions. Patients of both
groups were followed up at 2nd, 4th, 6th, 8th, 10th and 12th week. Those who cleared their warts on follow up visits
were not given further treatment. At the end of 12 weeks both groups were evaluated for treatment efficacy.
Results: Of these 64 study cases, 26 (40.625%) were males and 38 (59.375%) were females. Mean age of our
study cases was 27.59 ± 3.99 years (with minimum age was 20 years while maximum age was 35 years). Mean
age of our study cases in patients treated with intraleisonal MMR was 28.19 ± 3.95 years while patients treated
with cryotherapy was 27.00 ± 4.07 years. Mean weight of our study cases was 64.06 ± 6.16 kilograms (with
minimum weight was 54 kilograms and maximum was 78 kilograms). Mean weight in group A was 65.19 ± 6.52
kilograms while in Group B was 62.94 ± 5.67 kilograms. Majority of our study cases i.e. 46 (71.875%) were
having weight over 60 kilograms. Size of lesion was less than 1 cm in 36 (56.25%) of our study cases while in
remaining 28 (43.75%) was in the range of 1 to 1.5 centimeters. In 40 (62.5%) of our study cases, number of
lesions was 5-6. Mean no. of lesions was 2.48 ± 1.35. Mean no. of lesions in group A was 6 ± 0.88 while in
group B was also 6 ± 0.88. Mean duration of disease was 1.844 ± 0.67 months (with minimum duration was 1
month while maximum duration was 3 months). Our study results have indicated that majority of our study cases
i.e. 44 (68.75%) were having disease for more than 1.5 months. Mean duration of disease in group A was 1.94 ±
0.67 months while in group B was 1.75 ± 0.67 months. In group A efficacy was noted in 22 (68.75%) of our
study cases, while in group B efficacy was seen in 20 (62.5%) of our study cases. Majority of our overall study
cases were in middle socioeconomic group. While in Group A 50% were in high, 43.75% in middle and 6.25%
in low socioeconomic group. In Group B 50% was in middle, 31.25% in low and 18.75 in high socioeconomic
group.Conclusion: Efficacy of intraleisonal MMR injection is more than cryotherapy. It can be safely used for
the treatment of viral warts, as no serious side effects were observed in our study. Being cost effective, it
provides cheaper treatment option compared with cryotherapy which is quite expensive. Early treatment can help
patients to maintain routine daily lives and physical activities such as sports without any pain and side effects.
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Introduction:
Warts are firm papules with a rough surface, caused by human papillomavirus (HPV) infection. They range in
size from less than 1mm to over 1 cm and by confluence can form large masses1. Different clinical forms of
warts include common warts, palmoplantar warts, flat warts, filiform warts and anogenital warts2. HPV is a
small DNA virus that infects squamous epithelium and causes cell proliferation1. It has 29 genera formed by 189
genotypes of which 120 types are isolated from humans3. Viral warts and common warts are caused by types
1,2,4,27,292,4. The incidence of viral warts is found to be 12.94%.4
Different methods of treatment for warts include occlusion, topical salicylic acid, cryotherapy,
electrocautery, laser, topical chemotherapeutic agents, topical retinoic acid, oral cimetidine and immunotherapy2.
But no single therapy has been proven effective at achieving complete remission in every patient.
Cryotherapy is one of the most commonly used methods for treating warts. It involves freezing a wart with
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the use of a very cold substance, usually liquid nitrogen. The studies done previously on cryotherapy showed
variable cure rates ranging from 39%5 to 76.5%6. One study showed 41.7%7 cure rate with cryotherapy.
Topical salicylic acid is another very common treatment for warts. Salicylic acid has keratolytic effect 8,9. It
reduces the thickness of the warts1 by causing mechanical removal of epidermal cells infected with virus. In one
study the results of 6 trials were combined and it showed that topical salicylic acid had 75% cure rate8. Another
study showed 69%9 cure rate. Cryotherapy is considered a standard treatment for most warts2. Many studies
show that it is superior in efficacy when compared to other treatment option for warts. But a study combining the
results of 6 trials8 showed that topical salicylic acid therapy is safe and effective and there is no clear evidence
that other therapies are better than this. Salicylic acid, for topical use, is available over the counter and is very
cheap. But cryotherapy is not available in all hospitals, in our country and is a lot more costly10. On an average 3
to 4 visits to a doctor's office are required for cryotherapy10. But topical salicylic acid can be applied at home.
Also, cryotherapy is more painful than topical salicylic acid application10, 11.
Immunotherapy using intralesional MMR vaccine is a new therapeutic modality in the treatment of viral
warts. Immunotherapy appears to enhance the recognition of the virus by the immune system; this allows
clearance of treated as well as distant warts and helps to prevent future clinical infection through induction of a
long-term immunity to HPV 12-15. This study was conducted to compare two treatment modalities; the
immunotherapy and cryotherapy in the treatment of warts.
Material and methods:
Patients with warts attending the dermatology out-patient department were included in the study. Approval from
ethical committee of the hospital was taken. Disease was diagnosed on the basis of clinical features while
Pregnant ladies, lactating mothers and patients not willing to participate. Written informed consent was taken
from every patient. Patients were randomly allocated in to two groups by lottery method. Group A, having 32
patients, was injected with intralesional MMR vaccine (0.3ml) into the largest wart using an insulin syringe. The
injection was given on alternate weeks for maximum of 5 sessions. Group B, also having 32 patients, was given
cryotherapy by applying liquid nitrogen with a cotton tip applicator for 10 to 30 seconds until the ice ball
formation spreads to involve 1mm margin of surrounding normal skin, at weekly interval for maximum of 8
sessions. Patients of both groups were followed up at 2nd, 4th, 6th, 8th, 10th and 12th week. Those who cleared their
warts on follow up visits were not given further treatment. At the end of 12 weeks both groups were evaluated
for treatment efficacy. All data was entered and processed using software SPSS version 18. Mean and standard
deviation were calculated for age, weight, gender, size of warts, number of lesions and duration of disease of
patients. Frequencies and percentages were calculated for gender and efficacy of drugs in both groups.
Results:
Our study included a total of 64 cases of viral warts from OPD of Dermatology department of Nishtar Hospital
Multan. Our study included 26 (40.625%) males and 38 (59.375%) were females. Mean age of our study cases
was 27.59 ± 3.99 years (with minimum age was 20 years while maximum age was 35 years). Mean age of our
study cases in patients treated with intraleisonal MMR was 28.19 ± 3.95 years while patients treated with
cryotherapy was 27.00 ± 4.07 years. Mean weight of our study cases was 64.06 ± 6.16 kilograms (with minimum
weight was 54 kilograms and maximum was 78 kilograms). Mean weight in group A was 65.19 ± 6.52 kilograms
while in Group B was 62.94 ± 5.67 kilograms. Majority of our study cases i.e. 46 (71.875%) were having weight
over 60 kilograms. Size of lesion was less than 1 cm in 36 (56.25%) of our study cases while in remaining 28
(43.75%) was in the range of 1 to 1.5 centimeters. In 40 (62.5%) of our study cases, number of lesions was 5-6.
Mean no. of lesions was 2.48 ± 1.35. Mean no. of lesions in group A was 6 ± 0.88 while in group B was also 6 ±
0.88. Mean duration of disease was 1.844 ± 0.67 months (with minimum duration was 1 month while maximum
duration was 3 months). Our study results have indicated that majority of our study cases i.e. 44 (68.75%) were
having disease for more than 1.5 months. Mean duration of disease in group A was 1.94 ± 0.67 months while in
group B was 1.75 ± 0.67 months. In group A efficacy was noted in 22 (68.75%) of our study cases, while in
group B efficacy was seen in 20 (62.5%) of our study cases. Majority of our overall study cases were in middle
socioeconomic group. While in Group A 50% were in high, 43.75% in middle and 6.25% in low socioeconomic
group. In Group B 50% was in middle, 31.25% in low and 18.75 in high socioeconomic group.
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Table No. 1
Distribution of study cases by Efficacy.
(n = 64)
Efficacy
(n=64)
Group A Group B
Frequency % Frequency %
Yes
n=42
(65.625%)
22 68.75 20 62.5
No
n=22
(34.375%)
10 31.25 12 37.5
P – value 0.001
Discussion:
Our study included 26 (40.625%) males and 38 (59.375%) were females. Cockayne et al 16 reported 59 % female
patients in their study and 41 % male patients, these findings are similar to our study results. Bruggink et al 5
reported 56% female patients, in our study female gender was also predominated over males. Mean age of our
study cases was 27.59 ± 3.99 years (with minimum age was 20 years while maximum age was 35 years). Mean
age of our study cases in patients treated with intraleisonal MMR was 28.19 ± 3.95 years while patients treated
with cryotherapy was 27.00 ± 4.07 years. Cockayne et al 16 reported 24.3 years and 23.2 years, these findings are
close to that of our study results. Mean weight of our study cases was 64.06 ± 6.16 kilograms (with minimum
weight was 54 kilograms and maximum was 78 kilograms). Mean weight in group A was 65.19 ± 6.52 kilograms
while in Group B was 62.94 ± 5.67 kilograms. Majority of our study cases i.e. 46 (71.875%) were having weight
over 60 kilograms. Size of lesion was less than 1 cm in 36 (56.25%) of our study cases while in remaining 28
(43.75%) was in the range of 1 to 1.5 centimeters.
In 40 (62.5%) of our study cases, number of lesions was 5-6. Mean no. of lesions was 2.48 ± 1.35. Mean no.
of lesions in group A was 6 ± 0.88 while in group B was also 6 ± 0.88. Cockayne et al 16 reported mean value to
be 3.4 ± 3.6 in those treated with cryotherapy. This finding is bit lower than our study results, the reason for this
difference can be explained in the fact that we included only those with maximum no. of 7 lesions while
Cockayne et al included as many as 55 lesions (maximum value). Bruggink et al 5 reported median no. of lesions
as 2 lesions in both groups which is also lower than our findings. Mean duration of disease was 1.844 ± 0.67
months (with minimum duration was 1 month while maximum duration was 3 months). Our study results have
indicated that majority of our study cases i.e. 44 (68.75%) were having disease for more than 1.5 months. Mean
duration of disease in group A was 1.94 ± 0.67 months while in group B was 1.75 ± 0.67 months. Cockayne et al
16 reported very high duration of disease, this difference is also due to our inclusion criteria as we only included
with 3 months maximum disease duration cases. Majority of our overall study cases were in middle
socioeconomic group. While in Group A 50% were in high, 43.75% in middle and 6.25% in low socioeconomic
group. In Group B 50% was in middle, 31.25% in low and 18.75 in high socioeconomic group. In group A
efficacy was noted in 22 (68.75%) of our study cases, while in group B efficacy was seen in 20 (62.5%) of our
study cases. Similar results have been reported by Cockayne et al 16. Bruggink et al 5 reported 39 % cure rate
with cryotherapy. Dhar et al6 reported 76.5 % cure rate with Cryotherapy. Our findings are in middle of these
range values as reported by Bruggink et al5 and Dhar et al6. Nofal et al 17 reorted 74.5% cure rate with
intraleisonal MMR, while Gamil et al 18 reported 87 % cure rate with that of intraleisonal MMR. These findings
of Gibbs et al and Bart et al are close to our study results.
Conclusion:
Efficacy of intraleisonal MMR injection is more than cryotherapy. It can be safely used for the treatment of viral
warts, as no serious side effects were observed in our study. Being cost effective, it provides cheaper treatment
option compared with cryotherapy which is quite expensive. Early treatment can help patients to maintain
routine daily lives and physical activities such as sports without any pain and side effects.
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